Conclusions and Future Perspectives

During the last years, asthma treatment has entered a new fascinating era of trustworthy realities and promising perspectives [1]. These significant advances have been made possible by the recent relevant progress achieved towards a better understanding of the cellular and molecular mechanisms underlying asthma pathobiology [2, 3]. Undoubtedly, the most important new therapeutic tools available for the treatment of asthma, especially with regard to the more severe disease phenotypes, are biologic drugs [4]. Indeed, omalizumab and mepolizumab are already included in the step 5 of GINA guidelines for asthma management [5], and reslizumab has been recently approved by FDA [6]. Moreover, the current intense development of molecular-targeted therapies, many of which are undergoing advanced stages of clinical investigation, will probably lead in the next future to the introduction in real life of several other biologics indicated for asthma treatment [7–11].